| SCHEDULE OF INTANGIBLE ASSETS |
The
Company’s intangible assets at March 31, 2026 consisted of the following:
SCHEDULE OF INTANGIBLE ASSETS
| | |
Weighted-average useful life (in years) | | |
Cost | | |
Accumulated Amortization | | |
Net Carrying Value | |
| Definite-lived Intangibles | |
| | |
| | | |
| | | |
| | |
| Patents | |
19 | | |
$ | 239,000 | | |
$ | (70,000 | ) | |
$ | 169,000 | |
| Licenses | |
20 | | |
| 50,000 | | |
| (39,000 | ) | |
| 11,000 | |
| Acquired product rights | |
14 | | |
| 225,480,000 | | |
| (45,042,000 | ) | |
| 180,438,000 | |
| Customer relationships | |
7 | | |
| 190,000 | | |
| (152,000 | ) | |
| 38,000 | |
| Trade name | |
5 | | |
| 70,000 | | |
| (4,000 | ) | |
| 66,000 | |
| State pharmacy licenses | |
25 | | |
| 8,000 | | |
| (4,000 | ) | |
| 4,000 | |
| Indefinite-lived Intangibles | |
| | |
| | | |
| | | |
| | |
| Trademarks | |
Indefinite | | |
| 328,000 | | |
| - | | |
| 328,000 | |
| | |
| | |
$ | 226,365,000 | | |
$ | (45,311,000 | ) | |
$ | 181,054,000 | |
|
| SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS |
Amortization
expense for intangible assets for the three months ended March 31, 2026 and 2025 was as follows:
SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS
| | |
2026 | | |
2025 | |
| | |
For the Three Months Ended March 31, | |
| | |
2026 | | |
2025 | |
| Patents | |
$ | 5,000 | | |
$ | 3,000 | |
| Acquired NDAs | |
| 5,121,000 | | |
| 4,220,000 | |
| Customer relationships | |
| 3,000 | | |
| 3,000 | |
| Amortization
expense of intangible assets | |
$ | 5,129,000 | | |
$ | 4,226,000 | |
|
| SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE |
Estimated
future amortization expense for the Company’s intangible assets at March 31, 2026 was as follows:
SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE
| | |
| | |
| Remainder of 2026 | |
$ | 16,334,000 | |
| 2027 | |
| 19,369,000 | |
| 2028 | |
| 16,414,000 | |
| 2029 | |
| 16,244,000 | |
| 2030 | |
| 15,739,000 | |
| Thereafter | |
| 96,626,000 | |
| Intangible
assets | |
$ | 180,726,000 | |
|